Trastuzumab: beside a new treatment under test

261 studies: a new drug, cell therapy or vaccine is what the study tests. Page 2 of 3. Open to participants first (55), then studies with results posted, then the rest; newest registration first within each.

• Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast CancerTerminatedNCT00824733Phase 2Results postedReport a problem
• A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After TrastuzumabTerminatedNCT00567879Phase 1/2Results postedReport a problem
• A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast CancerCompletedNCT00567190Phase 3Results postedReport a problem
• Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast CancerCompletedNCT00458237Phase 1/2Results postedReport a problem
• Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast CancerCompletedNCT00426556Phase 1Results postedReport a problem
• Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast CancerCompletedNCT00404066Phase 2Results postedReport a problem
• Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for the Treatment of HER-2/Neu-Overexpressing Metastatic Breast CancerCompletedNCT00399529Phase 2Results postedReport a problem
• A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast CancerCompletedNCT00398567Phase 1/2Results postedReport a problem
• Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast CancerCompletedNCT00320385Phase 3Results postedReport a problem
• Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast CancerCompletedNCT00317720Phase 1/2Results postedReport a problem
• Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast CancerCompletedNCT00284180Phase 2Results postedReport a problem
• ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and LapatinibTerminatedNCT00272987Phase 3Results postedReport a problem
• Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast CancerCompletedNCT00266110Phase 2Results postedReport a problem
• Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast CancerCompletedNCT00258349Phase 1/2Results postedReport a problem
• Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving TrastuzumabCompletedNCT00194714Phase 1/2Results postedReport a problem
• Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast CancerTerminatedNCT00088985Phase 2Results postedReport a problem
• Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast CancerTerminatedNCT00079326Phase 2Results postedReport a problem
• Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast CancerCompletedNCT00077376Phase 2Results postedReport a problem
• Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu OverexpressionCompletedNCT00033514Phase 1/2Results postedReport a problem
• A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast CancerActive, not recruitingNCT07386938Phase 3Report a problem
• A Phase II Clinical Study of HLX22 in Combination With Trastuzumab and ChemotherapyActive, not recruitingNCT07176702Phase 2Report a problem
• Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer.WithdrawnNCT06884254Phase 3Report a problem
• Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid TumorsActive, not recruitingNCT06771622Phase 1/2Report a problem
• ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast CancerActive, not recruitingNCT06328738Phase 1Report a problem
• First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast CancerActive, not recruitingNCT06239467Phase 1Report a problem
• Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast CancerTerminatedNCT06038539Phase 3Report a problem
• Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.Status unknownNCT05985187Phase 3Report a problem
• A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric CancerActive, not recruitingNCT05980481Phase 2/3Report a problem
• Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast CancerActive, not recruitingNCT05802225Phase 3Report a problem
• RP-6306 in Patients With Advanced CancerCompletedNCT05605509Phase 2Report a problem
• A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid TumorsActive, not recruitingNCT05593094Phase 1/2Report a problem
• A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ TrastuzumabStatus unknownNCT05583383Not applicableReport a problem
• BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid TumorsTerminatedNCT05555251Phase 1/2Report a problem
• A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast CancerStatus unknownNCT05483439Phase 2Report a problem
• FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid TumorsTerminatedNCT05395052Phase 1Report a problem
• A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020TerminatedNCT05385705Phase 1Report a problem
• Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast CancerSuspendedNCT05378464Phase 1Report a problem
• Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and TrastuzumabStatus unknownNCT05346861Phase 3Report a problem
• A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast CancerActive, not recruitingNCT05346224Phase 3Report a problem
• A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)Active, not recruitingNCT05296798Phase 3Report a problem
• A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)CompletedNCT05283837Phase 3Report a problem
• CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) AdenocarcinomaTerminatedNCT05207722Phase 1/2Report a problem
• A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid TumorsActive, not recruitingNCT05143970Phase 1Report a problem
• A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor MalignanciesActive, not recruitingNCT05081609Phase 1/2Report a problem
• FT538 in Combination With Monoclonal Antibodies in Advanced Solid TumorsTerminatedNCT05069935Phase 1Report a problem
• A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)CompletedNCT05002127Phase 2/3Report a problem
• Efficacy and Safety of Pyrotinib in HER2 Positive Gastrointestinal TumorsStatus unknownNCT04960943Phase 2Report a problem
• Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric CancerActive, not recruitingNCT04908813Phase 2Report a problem
• Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast CancerStatus unknownNCT04717531Phase 2Report a problem
• Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.CompletedNCT04629846Phase 3Report a problem
• Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + DocetaxelActive, not recruitingNCT04514419Phase 3Report a problem
• DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast CancerCompletedNCT04509596Phase 1Report a problem
• Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast CancerCompletedNCT04508803Phase 2Report a problem
• Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid TumorsCompletedNCT04487236Phase 1Report a problem
• Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR CancersWithdrawnNCT04464967Phase 1/2Report a problem
• Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast CancerActive, not recruitingNCT04398914Phase 2Report a problem
• A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal CancerStatus unknownNCT04380012Phase 2Report a problem
• Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast CancerCompletedNCT04367090Phase 1Report a problem
• Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trialCompletedNCT04307329Phase 2Report a problem
• Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast CancerActive, not recruitingNCT04290793Phase 2/3Report a problem
• Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer PatientsCompletedNCT04253561Phase 1Report a problem
• TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing CancerCompletedNCT04246671Phase 1Report a problem
• A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.Status unknownNCT04236310Phase 2Report a problem
• TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and SurgeryStatus unknownNCT04197687Phase 2Report a problem
• A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial CancerActive, not recruitingNCT04188548Phase 1Report a problem
• Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast CancerSuspendedNCT04120246Phase 1Report a problem
• A Window-of-opportunity Study of Pelareorep in Early Breast CancerTerminatedNCT04102618Early Phase 1Report a problem
• KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast CancerStatus unknownNCT04034823Phase 2Report a problem
• SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction AdenocarcinomaActive, not recruitingNCT03950271Phase 2Report a problem
• Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBCStatus unknownNCT03910712Phase 2Report a problem
• A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast CancerStatus unknownNCT03863223Phase 3Report a problem
• Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast CancerStatus unknownNCT03756064Not applicableReport a problem
• Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast CancerCompletedNCT03588091Phase 3Report a problem
• A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing CancersActive, not recruitingNCT03448042Phase 1Report a problem
• HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast CancerCompletedNCT03387553Early Phase 1Report a problem
• FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid TumorsCompletedNCT03319459Phase 1Report a problem
• Immunotherapy Vaccine and Herceptin in Breast CancerCompletedNCT03014076Phase 1Report a problem
• A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)CompletedNCT03013218Phase 1Report a problem
• To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast CancerActive, not recruitingNCT03006172Phase 1Report a problem
• Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast CancerCompletedNCT02909751Phase 2Report a problem
• Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast CancerCompletedNCT02843126Phase 1/2Report a problem
• 64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain MetsWithdrawnNCT02735798Early Phase 1Report a problem
• Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study)CompletedNCT02705859Phase 1Report a problem
• Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving TrastuzumabCompletedNCT02649686Phase 1Report a problem
• A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)CompletedNCT02627274Phase 1Report a problem
• Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast CancerCompletedNCT02605915Phase 1Report a problem
• Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+TerminatedNCT02593708Phase 1Report a problem
• Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast CancerWithdrawnNCT02569489Phase 1Report a problem
• Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast CancerCompletedNCT02390427Phase 1Report a problem
• A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCISWithdrawnNCT02336984Phase 1/2Report a problem
• MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer PatientsTerminatedNCT02213744Phase 2/3Report a problem
• KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach CancerWithdrawnNCT02205463Phase 1Report a problem
• Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast CancerCompletedNCT02167854Phase 1Report a problem
• Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast CancerCompletedNCT02060253Phase 1Report a problem
• A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has SpreadActive, not recruitingNCT02057133Phase 1Report a problem
• A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast CancerCompletedNCT02025192Phase 1Report a problem
• A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced TumorsCompletedNCT02014909Phase 1Report a problem
• First-in-Human Dose Escalation Trial in Subjects With Advanced MalignanciesCompletedNCT01971515Phase 1Report a problem
• A Safety Study of SGN-LIV1A in Breast Cancer PatientsCompletedNCT01969643Phase 1Report a problem
• ARRY-380 + Trastuzuamab for Breast w/ Brain MetsCompletedNCT01921335Phase 1Report a problem

← Trastuzumab